Tamoxifen citrate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1977
- First approval year
- 1977
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Tamoxifen citrate
- Molecular weight
- 563.65
- Structure (SMILES)
- CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O
- emblon
- Emblon
- fentamox 10
- Fentamox 10
- fentamox 20
- Fentamox 20
- kentadex
- Kentadex
- kessar 10
- Kessar 10
- kessar 20
- Kessar 20
- noltam
- Noltam
- nolvadex
- Nolvadex
- nolvadex d
- Nolvadex d
- nolvadex fte
- Nolvadex fte
- oestrifen 10
- oestrifen 20
- oestrifen 40
- Oestrifen-10
- Oestrifen-20
And 9 more, listed on the interactive page.
- (Z)-2-(P-(1,2-DIPHENYL-1-BUTENYL)PHENOXY)-N,N-DIMETHYLETHYLAMINE CITRATE (1:1)
- ethanamine 2 4 1 2 diphenyl 1 butenyl phenoxy n n dimethyl z 2 hydroxy 1 2 3 propanetricarboxylate 1 1
- ETHANAMINE, 2-(4-(1,2-DIPHENYL-1-BUTENYL)PHENOXY)-N,N-DIMETHYL, (Z)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1)
- i c i 46474 citrate
- I.C.I.46474 CITRATE
- ici 46 474
- ICI 46,474
- ici 46474
- ICI-46474
- kessar
- Kessar
- nolvadex
- nourytam
- Nourytam
- nsc 180973
- nsc 757345
- NSC-180973
- NSC-757345
- tamofene
- Tamofene
- tamoxifen citrate
- Tamoxifen citrate
- TAMOXIFEN CITRATE [EP MONOGRAPH]
- TAMOXIFEN CITRATE [JAN]
- TAMOXIFEN CITRATE [MART.]
And 30 more, listed on the interactive page.
- ATC classification codes
- L02BA01
Sources for recorded values
- CAS registry numbers
- 54965-24-1
- ChEMBL ID
- CHEMBL786
- InChIKey
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N
- FDA ingredient codes (UNII)
- 7FRV7310N6
- 2733525
- 25010734
- 139148739
- 10324
- 40137
- Applicant
- MAYNE PHARMA COMMRCL
- Approval date
- 29 Oct 2005
- Application number
- NDA021807
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Boxed warning
- Yes
Administration routes
- Oral
Mechanisms of action
- Mechanism
- Estrogen receptor alpha modulator
- Action type
- MODULATOR
- Target
- Estrogen receptor
- Protein identifier
- P03372
Open Targets mechanisms
- Mechanism
- Estrogen receptor alpha modulator
- Action type
- MODULATOR
- Target
- Estrogen receptor
- Condition
- Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000389
- Subject identifier
- D008545
- Condition
- Carcinoma, Intraductal, Noninfiltrating
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000432
- Subject identifier
- D002285
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Breast Neoplasms, Male
- Highest recorded phase
- 2
- Condition identifier
- EFO:0006861
- Subject identifier
- D018567
- Condition
- Endometrial Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007532
- Subject identifier
- D016889
- Condition
- Desmoid Tumors
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009907
- Subject identifier
- D018222
- Condition
- Central Nervous System Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000158
- Subject identifier
- D016543
- Condition
- Breast Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:1000294
- Subject identifier
- D001943
- Condition
- Uveal Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000403
- Subject identifier
- D000098943
- Condition
- Paraganglioma
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000453
- Subject identifier
- D010235
- Condition
- Inflammatory Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000984
- Subject identifier
- D058922
- Condition
- Endometrial Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001512
- Subject identifier
- D016889
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001187
- Subject identifier
- D001749
- Condition
- Peritoneal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002087
- Subject identifier
- D010534
- Condition
- Fallopian Tube Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002158
- Subject identifier
- D005185
- Condition
- Liver Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002691
- Subject identifier
- D008113
- Condition
- Bipolar Disorder
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004985
- Subject identifier
- D001714
- Condition
- Breast Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0008170
- Subject identifier
- D010051
- Condition
- Endometrial Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0011962
- Subject identifier
- D016889
- Condition
- Carcinoma, Ovarian Epithelial
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0018364
- Subject identifier
- D000077216
- Condition
- Hereditary Breast and Ovarian Cancer Syndrome
- Highest recorded phase
- 2
- Condition identifier
- Orphanet:145
- Subject identifier
- D061325
- Condition identifier
- EFO_0000432
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009907
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000158
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000403
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001187
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002087
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002108
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002158
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002447
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002691
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002817
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002911
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004985
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004988
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005023
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005065
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005140
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006325
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006512
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006804
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0007256
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 1
And 7 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- carcinogenicity
- Warning
- Black Box Warning
- Effect
- immune system toxicity
- Warning
- Black Box Warning
- Effect
- neurotoxicity
- Warning
- Black Box Warning
- Effect
- respiratory toxicity
- Warning
- Black Box Warning
- Effect
- vascular toxicity
- Warning
- Black Box Warning
- Effect
- carcinogenicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- immune system toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- neurotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- respiratory toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- vascular toxicity
- Country
- United States
- Event
- acute myeloid leukaemia
- Reports
- 31
- Reporting signal score
- 64.1801
- Event
- adenomyosis
- Reports
- 9
- Reporting signal score
- 35.5107
- Event
- breast cancer
- Reports
- 41
- Reporting signal score
- 52.5873
- Event
- breast cancer metastatic
- Reports
- 72
- Reporting signal score
- 248.282
- Event
- breast cancer recurrent
- Reports
- 36
- Reporting signal score
- 124.991
- Event
- cataract
- Reports
- 35
- Reporting signal score
- 38.16
- Event
- cervical polyp
- Reports
- 19
- Reporting signal score
- 92.1181
- Event
- device related thrombosis
- Reports
- 10
- Reporting signal score
- 33.0032
- Event
- disease progression
- Reports
- 85
- Reporting signal score
- 86.7624
- Event
- endocervical curettage
- Reports
- 9
- Reporting signal score
- 56.6434
- Event
- endometrial atrophy
- Reports
- 14
- Reporting signal score
- 74.2394
- Event
- endometrial cancer
- Reports
- 28
- Reporting signal score
- 98.5125
- Event
- endometrial disorder
- Reports
- 13
- Reporting signal score
- 55.8142
- Event
- endometrial hyperplasia
- Reports
- 53
- Reporting signal score
- 261.722
- Event
- endometrial hypertrophy
- Reports
- 24
- Reporting signal score
- 118.984
- Event
- hepatic steatosis
- Reports
- 30
- Reporting signal score
- 46.983
- Event
- hormone receptor positive breast cancer
- Reports
- 9
- Reporting signal score
- 46.3775
- Event
- hot flush
- Reports
- 45
- Reporting signal score
- 52.87
- Event
- hysterectomy
- Reports
- 18
- Reporting signal score
- 39.2775
- Event
- hysteroscopy
- Reports
- 14
- Reporting signal score
- 77.7521
- Event
- leiomyoma
- Reports
- 8
- Reporting signal score
- 29.6383
- Event
- malignant neoplasm progression
- Reports
- 134
- Reporting signal score
- 238.8
- Event
- metastases to bone
- Reports
- 83
- Reporting signal score
- 233.91
- Event
- metastases to liver
- Reports
- 41
- Reporting signal score
- 87.8914
- Event
- metastases to lung
- Reports
- 29
- Reporting signal score
- 63.7161
And 15 more, listed on the interactive page.
- NCT00002460
- NCT00002528
- NCT00002529
- NCT00002542
- NCT00002579
- NCT00002580
- NCT00002581
- NCT00002582
- NCT00002644
- NCT00002646
- NCT00002679
- NCT00002680
- NCT00002720
- NCT00002755
- NCT00002772
- NCT00002777
- NCT00002784
- NCT00002864
- NCT00002967
- NCT00003013
- NCT00003016
- NCT00003032
- NCT00003035
- NCT00003042
- NCT00003050
And 73 more, listed on the interactive page.
- Dose
- 10 mg or 20 mg
- How often
- Once daily or multiple times daily
- Divide doses if > 20 mg per day
- Take for 5 years
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 0
- Polar surface area
- 12.47
- Calculated partition coefficient (ALogP)
- 6
- Prodrug
- Yes
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 8
- Heavy atoms
- 41
- Molecular formula
- C32H37NO8
- Monoisotopic mass
- 563.25191714
- Natural product
- No
- 0378-0144
- 0378-0274
- 0591-2472
- 0591-2473
- 51862-643
- 51862-682
- 59651-299
- 59651-300
- 63187-976
- 75907-058
- 75907-059
- 50090-0485
- 50090-0942
- 68071-3990
- 68071-5254
- 72162-2208
- 72162-2209
- 72162-2225
- Recorded assays
- 3,569
- Active assays
- 755
- Confirmatory
- Other
- Screening
- Summary
- Estrogen Antagonists
- Antineoplastic Agents, Hormonal
- Selective Estrogen Receptor Modulators
- Bone Density Conservation Agents
Solubility
- Median
- 2,710
- Mean
- 2,720
- Minimum
- 2,500
- Maximum
- 2,950
- Unit
- nM
- Assays
- 3
- Standard deviation
- 225.167
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Related records
Trials (380)
- 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
- A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
- A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
- A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
- A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma
- A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
- A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
- A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
- A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)
- A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
- A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
- A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).
- A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
- A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
- A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Approved for (2)
In development for (20)
- Bipolar disorder Phase 3
- Central nervous system neoplasm Phase 2
- Cutaneous melanoma Phase 2
- Desmoid tumor Phase 2
- Ductal breast carcinoma in situ Phase 3
- Endometrial cancer Phase 3
- Endometrial carcinoma Phase 3
- Fallopian tube cancer Phase 3
- Hereditary breast ovarian cancer syndrome Phase 2
- Inflammatory breast carcinoma Phase 3
- Liver cancer Phase 3
- Male breast carcinoma Phase 2
- Malignant epithelial tumor of ovary Phase 3
- Neoplasm Phase 2
- Ocular melanoma Phase 2
- Ovarian cancer Phase 1
- Paraganglioma Phase 2
- Peritoneum cancer Phase 3
- Urinary bladder cancer Phase 2
- Uterine corpus cancer Phase 3
Targets (1)
- ESR1 Estrogen receptor alpha modulator